[Claim]

[Claim 1] An adhesive patch having a pressure-sensitive adhesive layer comprising bisoprolol and/or a pharmaceutically acceptable salt thereof, wherein the composition of pressure-sensitive adhesive layer contains an acrylic polymer obtained by copolymerizing a (meth) acrylic ester with a (meth) acrylic acid comprising a carboxyl group.

[Claim 2] The adhesive patch according to claim 1, wherein the acrylic polymer contains substantially no alcoholic hydroxyl group in molecules.

[Claim 3] The adhesive patch according to claims 1 or 2, wherein the (meth) acrylic ester constituting the acrylic polymer is 2-ethylhexyl acrylate.

[Claim 4] The adhesive patch according to any one of claims 1 to 3, wherein the acrylic polymer is a 2-ethylhexyl acrylate vinyl acetate acrylic acid copolymer.

[Claim 5] The adhesive patch according to any one of claims 1 to 4, wherein the composition of the pressure-sensitive adhesive layer contains further an elastmeric polymer.

[Claim 6] The adhesive patch according to claim 5, wherein the elastmeric polymer is at least one kind selected from a group consisting of styrene-isoprene-styrene block copolymer, polyisobutylene, isoprene rubber, styrene-butadine-styrene block copolymer, styrene-butadine rubber and silicone rubber.

[Claim 7] The adhesive patch according to any one of claims

1 to 6, wherein the percutaneous absorption promoter is at least one kind selected from a group consisting of lauryl alcohol, myristyl alcohol, oleyl alcohol, isostearyl alcohol, diethyl sebacate, lauric diethanolamide, isopropyl myristate, glycerol monocaprate, glycerol monolaurate, glycerol monooleate, sorbitan monolaurate, propylene glycol monolaurate, polyoxyethylene lauryl ether, pyrothiodecane, an organic acid and a pharmaceutically acceptable salt thereof.

[Claim 8] The adhesive patch according to claim 7, wherein the organic acid and/or the pharmaceutically acceptable salt thereof are at least one kind selected from a group consisting of acetic acid, propionic acid, lactic acid, salicylic acid and pharmaceutically acceptable salts thereof.

[Claim 9] The adhesive patch according to claim 7, wherein the percutaneous absorption promoter is isopropyl myristate.

[Claim 10] The adhesive patch according to claim 9, wherein it contains further sodium acetate as the percutaneous absorption promoter.

[Claim 11] The adhesive patch according to any one of claims 1 to 10, wherein the drug is bisoprolol hemifumarate.

[Claim 12] The adhesive patch according to any one of claims 1 to 11, wherein the penetration rate of bisoprolol through the skin is 3-300 $\mu g/h \cdot cm^2$.